Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avoplacel - Pluri

Next Previous
Drug Profile

Avoplacel - Pluri

Alternative Names: Placenta-derived cell therapy - Pluri; PLX-R-18; PLX-RAD

Latest Information Update: 17 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Fukushima Medical University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluri; United States Department of Defense
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome; Preeclampsia; Stem cell engraftment; Aplastic anaemia; IgA nephropathy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute radiation syndrome
  • Phase I Stem cell engraftment
  • No development reported Aplastic anaemia; Chemical burns

Most Recent Events

  • 05 Mar 2025 Pluri signs an exclusive collaboration agreement with Hemafund for stockpiling, distribution, and potential clinical advancement of PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome in Ukraine
  • 25 Jul 2024 Avoplacel is still in phase-I development in Stem cell engraftment (In the elderly, In adults) in the US (IM, Injection) (Pluristem Therapeutics pipeline, July 2024)
  • 06 Jun 2024 Adverse events and pharmacodynamics data from a preclinical study in Acute radiation syndrome released by Pluri

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top